Pfizer's Fablyn gets EU positive opinion
This article was originally published in Scrip
Executive Summary
Pfizer's selective oestrogen receptor modulator (SERM) Fablyn (lasofoxifene, 500μg film-coated tablets) has been granted a positive opinion by the EU's CHMPfor the treatment of osteoporosis in postmenopausal women at increased risk of fracture.